Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiencyRichard L. Wasserman, Johann Bichler, Isaac Melamed et al.|European Journal of Pharmaceutical Sciences|2009Cited by 48
Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USAArye Rubinstein, Leman Yel, Mohsen Mabudian et al.|Clinical Immunology|2023Cited by 1